title: Reply to S. Barni et Al and M. Sun et Al.
authors.affiliation: Institut Gustave Roussy, Villejuif, France escudier@igr.fr.
authors.forename: Bernard
authors.initials: B
authors.lastname: Escudier
authors.affiliation: Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy.
authors.forename: Camillo
authors.initials: C
authors.lastname: Porta
authors.affiliation: Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, United Kingdom.
authors.forename: Thomas
authors.initials: T
authors.lastname: Powles
authors.affiliation: Cambridge University Health Partners, Cambridge, United Kingdom.
authors.forename: Tim
authors.initials: T
authors.lastname: Eisen
authors.affiliation: San Camillo Forlanini Hospital, Rome, Italy.
authors.forename: Cora N
authors.initials: CN
authors.lastname: Sternberg
authors.affiliation: GlaxoSmithKline, Uxbridge, United Kingdom.
authors.forename: Faisal
authors.initials: F
authors.lastname: Mehmud
authors.affiliation: Northwestern University Feinberg School of Medicine, Chicago, IL.
authors.forename: David
authors.initials: D
authors.lastname: Cella
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D057240:Patient Preference; D011743:Pyrimidines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D013449:Sulfonamides / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides